Higher Relapse Rate With Rituximab vs Ocrelizumab in MS Regi

Rituximab did not show non-inferiority in comparative effectiveness study

Related Keywords

Denmark , Danish , Judy George , Rituximab Rituxan , Research In Multiple Sclerosis , European Committee For Treatment , Danish Multiple Sclerosis Registry , Expanded Disability Status Scale , Medpage Today ,